MC (Moelis) 5-Year Sharpe Ratio : 0.47 (As of Jul. 18, 2025)

View and export this data going back to 2014. Start your Free Trial

What is Moelis 5-Year Sharpe Ratio?

The 5-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past five years. As of today (2025-07-18), Moelis's 5-Year Sharpe Ratio is 0.47.

Competitive Comparison of Moelis's 5-Year Sharpe Ratio

For the Capital Markets subindustry, Moelis's 5-Year Sharpe Ratio, along with its competitors' market caps and 5-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moelis's 5-Year Sharpe Ratio Distribution in the Capital Markets Industry

For the Capital Markets industry and Financial Services sector, Moelis's 5-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Moelis's 5-Year Sharpe Ratio falls into.

Save Embed

;

Save Embed

;

Moelis 5-Year Sharpe Ratio Calculation

The 5-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last five years. A stock / portfolio's 5-Year Sharpe Ratio can be calculated by dividing the difference between the five-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past five years.

Moelis (NYSE:MC) 5-Year Sharpe Ratio Explanation

The 5-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past five years. It is calculated as the annualized result of the average five-year monthly excess returns divided by its standard deviation in the five-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Moelis 5-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of Moelis's 5-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Moelis Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Capital Markets » Moelis & Co (NYSE:MC) » Definitions » 5-Year Sharpe Ratio

Comparable Companies

Traded in Other Exchanges

17M:Germany

Address

399 Park Avenue, 4th Floor, New York, NY, USA, 10022

Website

https://www.moelis.com

Moelis & Co is an independent investment bank that provides strategic and financial advice to a diverse client base, including corporations, financial sponsors, governments, and sovereign wealth funds. The company assists its clients in achieving their strategic goals by offering comprehensive, globally integrated financial advisory services across all industry sectors. It also advises clients on their critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. it generates revenue from advisory transactions. The firm derives a majority of its revenue from the United States followed by Europe and the rest of the World.

Executives

Kenneth Shropshire	director	C/O MOELIS & COMPANY, 399 PARK AVENUE, 5TH FLOOR, NEW YORK NY 10011
Kenneth Moelis	director, 10 percent owner, officer: Chairman and CEO	C/O MOELIS & COMPANY, 399 PARK AVENUE, 5TH FLOOR, NEW YORK NY 10022
Osamu R. Watanabe	officer: General Counsel and Secretary	C/O MOELIS & COMPANY, 399 PARK AVENUE, 5TH FLOOR, NEW YORK NY 10022
Navid Mahmoodzadegan	director, officer: Managing Director	C/O MOELIS & COMPANY, 399 PARK AVENUE, 5TH FLOOR, NEW YORK NY 10022
Jeffrey Raich	director, officer: Managing Director	C/O MOELIS & COMPANY, 399 PARK AVENUE, 5TH FLOOR, NEW YORK NY 10022
Joseph Simon	officer: Chief Financial Officer	C/O MOELIS & COMPANY, 399 PARK AVENUE, 5TH FLOOR, NEW YORK NY 10022
Eric Cantor	director	C/O MOELIS & COMPANY, 399 PARK AVENUE, 5TH FLOOR, NEW YORK NY 10022
Christopher Callesano	officer: SVP & Principal Acct Officer	C/O MOELIS & COMPANY, 399 PARK AVENUE, 5TH FLOOR, NEW YORK NY 10022
Ciafone Katherine Pilcher	officer: Chief Operating Officer	399 PARK AVE, NEW YORK NY 10022
Elizabeth Crain	officer: Chief Operating Officer	C/O MOELIS & COMPANY, 399 PARK AVENUE, 5TH FLOOR, NEW YORK NY 10022
Laila Worrell	director	399 PARK AVENUE, NEW YORK NY 10022
Yolonda C Richardson	director	399 PARK AVENUE, NEW YORK NY 10022
Leaman J Richard Iii	director, officer: Managing Partner	C/O MOELIS & COMPANY, 399 PARK AVENUE, 5TH FLOOR, NEW YORK NY 10022
John A Allison	director	PO BOX 1250, WINSTON SALEM NC 27102-1250
Yvonne Greenstreet	director	PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, PARSIPPANY NJ 07054